PRESS RELEASE
News
-
-
PRESS RELEASE
MindBio Begins Landmark Phase 2B Take-Home Microdosing (MB22001) Clinical Trial in Patients with Major Depressive Disorder
MindBio Therapeutics Corp. commences Phase 2B clinical trial for MB22001 in Major Depressive Disorder patients, following successful Phase 2A trial with significant results -
-
-
PRESS RELEASE
MindBio Therapeutics Receives Final Regulatory Approval to Conduct Phase 2B Randomised Controlled Trial Microdosing Mb22001 in Patients Diagnosed with Major Depressive Disorder
Ethics and regulatory approvals finalized for world-first take-home use of psychedelic medicine MB22001 in Phase 2B randomized controlled trial for Major Depressive Disorder by MindBio Therapeutics Corp -
-
-
PRESS RELEASE
MindBio Therapeutics Announces Positive Depression Data from World-First Phase 2a Take-Home Microdosing Trial
MindBio announces positive top line data from its world-first take-home microdosing depression clinical trial using MB22001. Patients experienced a 60% reduction in depressive symptoms with an impressive mean 14.1 point drop in MADRS score over 8 weeks -
PRESS RELEASE
MindBio Therapeutics Completes World First Take Home Phase 2a Microdosing Depression Trial
MindBio Therapeutics Corp. completes landmark Phase 2a clinical trial in Major Depressive Disorder patients with regulatory approvals for take-home use of proprietary microdose LSD MB22001. Phase 2B trial in late-stage cancer patients ongoing. CEO Justin Hanka announces pivotal moment for psychiatric medicine development -
PRESS RELEASE
MindBio Therapeutics Nears Completion of Landmark Phase 2a LSD Microdosing (MB22001) Clinical Trial in Depressed Patients
MindBio Therapeutics Corp. is nearing completion of its Phase 2a clinical trial using MB22001 in patients with Major Depressive Disorder. The company expects top line results to be announced in March 2024. MindBio is conducting trials with regulatory approvals for take-home use of a special form of LSD in microdoses, aiming to treat mental health conditions
